ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott sold 50,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $705,000.00. Following the sale, the chief financial officer now owns 7,424 shares of the company’s stock, valued at approximately $104,678.40. This trade represents a 87.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

ARS Pharmaceuticals Price Performance

Shares of SPRY opened at $14.52 on Friday. ARS Pharmaceuticals, Inc. has a 1 year low of $7.55 and a 1 year high of $18.51. The stock has a 50 day simple moving average of $13.54 and a two-hundred day simple moving average of $12.87. The firm has a market cap of $1.43 billion, a P/E ratio of -28.47 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). The business had revenue of $7.97 million during the quarter, compared to analysts’ expectations of $7.48 million. On average, equities analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Institutional Trading of ARS Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Bernard Wealth Management Corp. purchased a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $27,000. ANTIPODES PARTNERS Ltd bought a new position in ARS Pharmaceuticals during the 1st quarter worth approximately $37,000. PNC Financial Services Group Inc. grew its position in ARS Pharmaceuticals by 78,100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock worth $49,000 after acquiring an additional 3,905 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $73,000. Finally, BNP Paribas Financial Markets bought a new stake in ARS Pharmaceuticals in the fourth quarter valued at approximately $75,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SPRY has been the topic of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Scotiabank initiated coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Wall Street Zen cut shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Finally, Oppenheimer started coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.